EFLA® 945 Enters German Market

HAIFA, IsraelEFLA® 945, a red vine leaf extract (Vitis vinifera L.) from Frutarom, entered the German vascular health market after the European Patent Office (EPO) revoked Böhringer Ingelheim`s patent EP 1 300 084 "composition for treatment of chronic venous insufficiencies (CVI) comprising of an extract of red vine leaves."

On September 20, 2011, EPOs final conclusion to revoke this patent opened new horizons for our Vitis vinifera L. aqueous extract, Red Vine Leaf EFLA 945" said Raul Cortada, global vice president of sales and marketing for Frutarom Health. Our Red Vine Leaf Extract EFLA® 945 is scientifically backed by bibliographic studies and its triple-powerful standardization of three markers: polyphenols, anthocyanins and trans-resveratrol. This makes it a cutting-edge natural ingredient in the vascular health market."

EFLA 945 contains polyphenols and anthocyanins and trans-resveratrol designed to inhibit the platelet agglutination involved in heavy leg syndrome and varicose veins. EFLA 945 supports vascular health via three mechanisms: countering CVI resulting in vessel protection, promoting lipid metabolism and reducing plaque formation for atherosclerosis.

Earlier this year, Frutarom said its yearly revenues increased by 8 percent in local currency and 6.1 percent in U.S. dollars to $US 451.1 million in 2010. In its 2010 annual and fourth-quarter results, the company also said it saw a 33-percent rise in operating profit to $US 63 million and a net profit of $US 44.1 million, which is a record for the company.